Abstract:

Background: Atherosclerosis and coronary artery disease are both caused by dyslipidemia, which has been identified as the primary cause. The statin medication class is the most often recommended therapy for dyslipidemia. Among these, atorvastatin and rosuvastatin, a relatively new medication, are more commonly recommended. The goal of the study was to evaluate the efficacy of rosuvastatin and atorvastatin in the treatment of dyslipidemia.Methods and Material: Patients with dyslipidemia between the ages of 30 and 72 were eligible. One of two therapy groups was allocated to the patients. A total of 250 patients were randomly divided into two groups, each with 125 patients, and labeled Group I and Group II. For 12 weeks, Group I was given rosuvastatin (10 mg tablet OD) while Group II was given atorvastatin (10 mg tablet OD). The lipid profile low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), triglycerides (TG), and very-low-density lipoprotein cholesterol (VLDL-C) were measured before the start of therapy and after 12 weeks. Percentage changes from baseline were calculated and adverse effects were recorded. Results: During the 11 months study, A total of 250 patients were screened for the study, of which males represented 63.60% (n = 159), female 36.40% (91) of the population, male and female ratio was 1.7:1. A total of 250 patients were divided randomly into two groups of 125 patients each and assigned as group I (male 80, female 30) and Group II (male 79, female 31. The group-I mean age was 53.66 ± 7.69 and group-II mean age 52.75 ± 6.89. Group I received rosuvastatin (10 mg tablet OD) and Group II received atorvastatin (10 mg tablet OD) for 12 weeks. The levels of serum TC and LDL-C are decreased by 38.01% and 47.55 % respectively with the use of rosuvastatin (Group-I) after 12 weeks. atorvastatin 10 mg/day ((Group-II)for 12 weeks resulted in a statistically significant fall in levels of serum TC and LDL-C by 23.50 % and 29.79 %.Conclusions: Generally, medication of Rosuvastatin could reach a better lipid-reducing effect and yield a higher attainment rate of LDL-C and TC than Atorvastatin in the same dose in high-risk hyperlipidemic Indian patients.

Keywords: